 | • レポートコード：GIR-2104Z09721 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、骨髄異形成症候群（MDS）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。骨髄異形成症候群（MDS）治療の種類別市場規模（アザシチジン、レナリドマイド、デシタビン、デフェラシロクス）、用途別市場規模（単系統異形成を伴う難治性血球減少症、環状鉄芽球を伴う難治性貧血、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・骨髄異形成症候群（MDS）治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Novartis AG、Celgene Corporation、Otsuka Pharmaceutical Co., Ltd、Sandoz Inc、Dr Reddys Laboratories Limited、Pharmascience Inc、Accord Healthcare Ltd、Mylan N.V. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：アザシチジン、レナリドマイド、デシタビン、デフェラシロクス ・用途別分析2016年-2026年：単系統異形成を伴う難治性血球減少症、環状鉄芽球を伴う難治性貧血、その他 ・骨髄異形成症候群（MDS）治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・骨髄異形成症候群（MDS）治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・骨髄異形成症候群（MDS）治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・骨髄異形成症候群（MDS）治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・骨髄異形成症候群（MDS）治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Myelodysplastic Syndrome (MDS) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Myelodysplastic Syndrome (MDS) Treatment size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Myelodysplastic Syndrome (MDS) Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Myelodysplastic Syndrome (MDS) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Market segment by Application can be divided into
Refractory Cytopenia with Unilineage Dysplasia
Refractory Anemia with Ringed Sideroblasts
Others
The key market players for global Myelodysplastic Syndrome (MDS) Treatment market are listed below:
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience Inc
Accord Healthcare Ltd
Mylan N.V.
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Myelodysplastic Syndrome (MDS) Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Azacitidine
1.2.3 Lenalidomide
1.2.4 Decitabine
1.2.5 Deferasirox
1.3 Market Analysis by Application
1.3.1 Overview: Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Refractory Cytopenia with Unilineage Dysplasia
1.3.3 Refractory Anemia with Ringed Sideroblasts
1.3.4 Others
1.4 Global Myelodysplastic Syndrome (MDS) Treatment Market Size & Forecast
1.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales in Value (2016-2026))
1.4.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales in Volume (2016-2026)
1.4.3 Global Myelodysplastic Syndrome (MDS) Treatment Price by Type (2016-2026) & (USD/Unit)
1.5 Global Myelodysplastic Syndrome (MDS) Treatment Production Capacity Analysis
1.5.1 Global Myelodysplastic Syndrome (MDS) Treatment Total Production Capacity (2016-2026)
1.5.2 Global Myelodysplastic Syndrome (MDS) Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Myelodysplastic Syndrome (MDS) Treatment Market Drivers
1.6.2 Myelodysplastic Syndrome (MDS) Treatment Market Restraints
1.6.3 Myelodysplastic Syndrome (MDS) Treatment Trends Analysis
2 Manufacturers Profiles
2.1 Novartis AG
2.1.1 Novartis AG Details
2.1.2 Novartis AG Major Business
2.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Product and Services
2.1.4 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Celgene Corporation
2.2.1 Celgene Corporation Details
2.2.2 Celgene Corporation Major Business
2.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Product and Services
2.2.4 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Otsuka Pharmaceutical Co., Ltd
2.3.1 Otsuka Pharmaceutical Co., Ltd Details
2.3.2 Otsuka Pharmaceutical Co., Ltd Major Business
2.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Product and Services
2.3.4 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Sandoz Inc
2.4.1 Sandoz Inc Details
2.4.2 Sandoz Inc Major Business
2.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Product and Services
2.4.4 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Dr Reddys Laboratories Limited
2.5.1 Dr Reddys Laboratories Limited Details
2.5.2 Dr Reddys Laboratories Limited Major Business
2.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Product and Services
2.5.4 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Pharmascience Inc
2.6.1 Pharmascience Inc Details
2.6.2 Pharmascience Inc Major Business
2.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Product and Services
2.6.4 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Accord Healthcare Ltd
2.7.1 Accord Healthcare Ltd Details
2.7.2 Accord Healthcare Ltd Major Business
2.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Product and Services
2.7.4 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Mylan N.V.
2.8.1 Mylan N.V. Details
2.8.2 Mylan N.V. Major Business
2.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Product and Services
2.8.4 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturer
3.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Myelodysplastic Syndrome (MDS) Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Myelodysplastic Syndrome (MDS) Treatment Manufacturer Market Share
3.4.2 Top 6 Myelodysplastic Syndrome (MDS) Treatment Manufacturer Market Share
3.5 Global Myelodysplastic Syndrome (MDS) Treatment Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Myelodysplastic Syndrome (MDS) Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size by Region
4.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales in Volume by Region (2016-2026)
4.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2016-2026)
4.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026)
4.3 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026)
4.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026)
4.5 South America Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026)
4.6 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales in Volume by Type (2016-2026)
5.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2016-2026)
5.3 Global Myelodysplastic Syndrome (MDS) Treatment Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales in Volume by Application (2016-2026)
6.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2016-2026)
6.3 Global Myelodysplastic Syndrome (MDS) Treatment Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2026)
7.2 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2026)
7.3 North America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country
7.3.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales in Volume by Country (2016-2026)
7.3.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2026)
8.2 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2026)
8.3 Europe Myelodysplastic Syndrome (MDS) Treatment Market Size by Country
8.3.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales in Volume by Country (2016-2026)
8.3.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2026)
9.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2026)
9.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Size by Region
9.3.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2026)
10.2 South America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2026)
10.3 South America Myelodysplastic Syndrome (MDS) Treatment Market Size by Country
10.3.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales in Volume by Country (2016-2026)
10.3.2 South America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2026)
11.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2026)
11.3 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Size by Country
11.3.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Myelodysplastic Syndrome (MDS) Treatment Typical Distributors
12.3 Myelodysplastic Syndrome (MDS) Treatment Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type, (USD Million), 2021-2026
Table 2. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Application, (USD Million), 2021-2026
Table 3. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 4. Novartis AG Major Business
Table 5. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Product and Services
Table 6. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 8. Celgene Corporation Major Business
Table 9. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Product and Services
Table 10. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Otsuka Pharmaceutical Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 12. Otsuka Pharmaceutical Co., Ltd Major Business
Table 13. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Product and Services
Table 14. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Sandoz Inc Basic Information, Manufacturing Base and Competitors
Table 16. Sandoz Inc Major Business
Table 17. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Product and Services
Table 18. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Dr Reddys Laboratories Limited Basic Information, Manufacturing Base and Competitors
Table 20. Dr Reddys Laboratories Limited Major Business
Table 21. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Product and Services
Table 22. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Pharmascience Inc Basic Information, Manufacturing Base and Competitors
Table 24. Pharmascience Inc Major Business
Table 25. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Product and Services
Table 26. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Accord Healthcare Ltd Basic Information, Manufacturing Base and Competitors
Table 28. Accord Healthcare Ltd Major Business
Table 29. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Product and Services
Table 30. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Mylan N.V. Basic Information, Manufacturing Base and Competitors
Table 32. Mylan N.V. Major Business
Table 33. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Product and Services
Table 34. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturer (2019-2021e) & (K Units)
Table 36. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Myelodysplastic Syndrome (MDS) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Myelodysplastic Syndrome (MDS) Treatment Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Myelodysplastic Syndrome (MDS) Treatment Production Site of Key Manufacturer
Table 40. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2016-2021e) & (K Units)
Table 41. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2021-2026) & (K Units)
Table 42. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 43. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 44. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2021e) & (K Units)
Table 45. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2021-2026) & (K Units)
Table 46. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2016-2021e) & (USD Million)
Table 47. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 48. Global Myelodysplastic Syndrome (MDS) Treatment Price by Type (2016-2021e) & (USD/Unit)
Table 49. Global Myelodysplastic Syndrome (MDS) Treatment Price by Type (2021-2026) & (USD/Unit)
Table 50. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2021e) & (K Units)
Table 51. Global Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2021-2026) & (K Units)
Table 52. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2016-2021e) & (USD Million)
Table 53. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 54. Global Myelodysplastic Syndrome (MDS) Treatment Price by Application (2016-2021e) & (USD/Unit)
Table 55. Global Myelodysplastic Syndrome (MDS) Treatment Price by Application (2021-2026) & (USD/Unit)
Table 56. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2016-2021e) & (K Units)
Table 57. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2021-2026) & (K Units)
Table 58. North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 59. North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 60. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2021e) & (K Units)
Table 61. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2021-2026) & (K Units)
Table 62. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2021e) & (K Units)
Table 63. North America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2021-2026) & (K Units)
Table 64. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2016-2021e) & (K Units)
Table 65. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2021-2026) & (K Units)
Table 66. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 67. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 68. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2021e) & (K Units)
Table 69. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2021-2026) & (K Units)
Table 70. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2021e) & (K Units)
Table 71. Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2021-2026) & (K Units)
Table 72. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2016-2021e) & (K Units)
Table 73. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Region (2021-2026) & (K Units)
Table 74. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 75. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 76. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2021e) & (K Units)
Table 77. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2021-2026) & (K Units)
Table 78. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2021e) & (K Units)
Table 79. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2021-2026) & (K Units)
Table 80. South America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2016-2021e) & (K Units)
Table 81. South America Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2021-2026) & (K Units)
Table 82. South America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 83. South America Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 84. South America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2021e) & (K Units)
Table 85. South America Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2021-2026) & (K Units)
Table 86. South America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2021e) & (K Units)
Table 87. South America Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2021-2026) & (K Units)
Table 88. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2016-2021e) & (K Units)
Table 89. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Country (2021-2026) & (K Units)
Table 90. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 91. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 92. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2016-2021e) & (K Units)
Table 93. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Type (2021-2026) & (K Units)
Table 94. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2016-2021e) & (K Units)
Table 95. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Application (2021-2026) & (K Units)
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Myelodysplastic Syndrome (MDS) Treatment Typical Distributors
Table 99. Myelodysplastic Syndrome (MDS) Treatment Typical Customers
List of Figures
Figure 1. Myelodysplastic Syndrome (MDS) Treatment Picture
Figure 2. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type in 2020
Figure 3. Azacitidine
Figure 4. Lenalidomide
Figure 5. Decitabine
Figure 6. Deferasirox
Figure 7. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application in 2020
Figure 8. Refractory Cytopenia with Unilineage Dysplasia
Figure 9. Refractory Anemia with Ringed Sideroblasts
Figure 10. Others
Figure 11. Global Myelodysplastic Syndrome (MDS) Treatment Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 12. Global Myelodysplastic Syndrome (MDS) Treatment Market Size and Forecast (2016-2026) & (USD Million)
Figure 13. United States Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Canada Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Mexico Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. Germany Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. France Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. United Kingdom Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Russia Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Italy Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. China Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Japan Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Korea Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. India Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Australia Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Brazil Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Egypt Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. South Africa Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Turkey Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Global Myelodysplastic Syndrome (MDS) Treatment Sales (2016-2026) & (K Units)
Figure 33. Global Myelodysplastic Syndrome (MDS) Treatment Production Capacity (2016-2026) & (K Units)
Figure 34. Global Myelodysplastic Syndrome (MDS) Treatment Production Capacity by Geographic Region: 2020 VS 2021
Figure 35. Myelodysplastic Syndrome (MDS) Treatment Market Drivers
Figure 36. Myelodysplastic Syndrome (MDS) Treatment Market Restraints
Figure 37. Myelodysplastic Syndrome (MDS) Treatment Market Trends
Figure 38. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Manufacturer in 2020
Figure 39. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Manufacturer in 2020
Figure 40. Myelodysplastic Syndrome (MDS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 41. Top 3 Myelodysplastic Syndrome (MDS) Treatment Manufacturer (Revenue) Market Share in 2020
Figure 42. Top 6 Myelodysplastic Syndrome (MDS) Treatment Manufacturer (Revenue) Market Share in 2020
Figure 43. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2016-2026)
Figure 44. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region (2016-2026)
Figure 45. North America Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026) & (USD Million)
Figure 46. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026) & (USD Million)
Figure 47. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026) & (USD Million)
Figure 48. South America Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026) & (USD Million)
Figure 49. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue (2016-2026) & (USD Million)
Figure 50. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2016-2026)
Figure 51. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2016-2026)
Figure 52. Global Myelodysplastic Syndrome (MDS) Treatment Price by Type (2016-2026) & (USD/Unit)
Figure 53. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2016-2026)
Figure 54. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Application (2016-2026)
Figure 55. Global Myelodysplastic Syndrome (MDS) Treatment Price by Application (2016-2026) & (USD/Unit)
Figure 56. North America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2016-2026)
Figure 57. North America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2016-2026)
Figure 58. North America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2016-2026)
Figure 59. North America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2016-2026)
Figure 60. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2016-2026)
Figure 61. Europe Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2016-2026)
Figure 62. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2016-2026)
Figure 63. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2016-2026)
Figure 64. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Region (2016-2026)
Figure 66. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Region (2016-2026)
Figure 67. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2016-2026)
Figure 68. South America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2016-2026)
Figure 69. South America Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2016-2026)
Figure 70. South America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2016-2026)
Figure 71. South America Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2016-2026)
Figure 72. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Country (2016-2026)
Figure 74. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type (2016-2026)
Figure 75. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2016-2026)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界の骨髄異形成症候群（MDS）治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Myelodysplastic Syndrome (MDS) Therapeutics Market The global Myelodysplastic Syndrome (MDS) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in …- 世界の骨髄異形成症候群（MDS）治療薬市場 2021：企業別、地域別、種類・用途別 The Myelodysplastic Syndrome (MDS) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
- 世界の骨髄異形成症候群市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Myelodysplastic Syndrome Market The global Myelodysplastic Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the …
- 世界のドラベ症候群治療市場規模・現状・予測（2021年-2027年） Dravet syndrome is a rare, severe form of intractable epilepsy. It occurs due to a mutation in the SCN1A gene, which is required for the proper function of brain cells. Although there is no cure for Dravet syndrome, most treatments aim to reduce seizures. First line anti-seizure medications include …
- 世界のバーター症候群治療市場規模・現状・予測（2021年-2027年） Bartter syndrome is a rare genetic disorder that causes specific defects in kidney function. The global market for Bartter syndrome treatment is expected to witness a moderate growth rate over the forecast period. Market Analysis and Insights: Global Bartter Syndrome Treatment Market The global Bart…